key: cord-0761258-cueyg0kh
authors: Maruyama, Ayano; Ohshita, Akifumi; Katoh, Norito
title: Severe skin ulcer in systemic scleroderma due to severe acute respiratory syndrome coronavirus 2 infection
date: 2021-04-21
journal: J Dermatol
DOI: 10.1111/1346-8138.15920
sha: e719e92f5ccb8c12b57e1e65cc851c7262b2f637
doc_id: 761258
cord_uid: cueyg0kh

nan

Dear Editor,

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is still spreading rapidly. SARS-CoV-2 infection reportedly has a variety of dermatological manifestations. [1] [2] [3] [4] [5] We report a rare case of a patient with systemic scleroderma (SSc) who developed severe skin ulcers and ischemia on her toes without systemic deterioration associated with SARS-CoV-2 infection.

A 56-year-old Japanese woman with SSc and systemic lupus erythematosus was treated with long-term oral prednisone 10 mg daily and bosentan 62.5 mg daily, and the disease was stable for a long time. Although she had significant chilblain-like lesions during winter, the ulcers on her toes did not get worse (Figure 1a ). The chilblainlike lesions always improved in the spring. She received prostaglandin injections twice weekly during winter, and her hands and feet were well protected and treated for skin ulcers. However, at the end of December 2020, she noticed severe toe pain, her toes were pale, and the ulcers produced more exudate (Figure 1b ).

Her symptoms did not improve; therefore, 10 days later, she presented to our department. There was no fever, upper respiratory symptoms, or malaise. Blood test results did not show any abnormality. Chest computerized tomography indicated no complications, such as interstitial pneumonia and severe ischemic limb.

She was not exposed to cold and atmospheric temperatures were not lower than usual, but the severe pain, ischemia, and ulcers on the toes, persisted. At that time, the coronavirus disease 2019 (COVID-19) pandemic had begun in Japan, and we confirmed she had SARS-CoV-2 infection with a positive polymerase chain reaction (PCR) test. Therefore, we diagnosed her with severe skin ulcers due to SARS-CoV-2 infection. The pale appearance and severe pain resolved rapidly within 5 days, without any systemic symptoms associated with SARS-CoV-2. The size of the skin ulcer and amount of exudates decreased (Figure 1c) . Afterwards, SARS-CoV-2 PCR test was negative.

Pseudo-chilblains, are reportedly the most common skin manifestations of COVID-19, and are more prevalent in younger patients. [3] [4] [5] In contrast, vaso-occlusive lesions (livedo racemosa, retiform purpura, and acral ischemia) are the least common, and tend to affect elderly patients. Patients with vaso-occlusive lesions due to COVID-19 are at a higher risk of severe pneumonia than those with other skin conditions; furthermore, it reportedly appears late in the course of the illness. 3 

Cutaneous manifestations of COVID-19: A preliminary review

COVID-19 and cutaneous manifestations: a systematic review

Skin manifestations of COVID-19: a worldwide review

Skin manifestations of COVID-19

Cutaneous manifestations of COVID-19: an evidence-based review

https://orcid.org/0000-0003-2519-8378Norito Katoh https://orcid.org/0000-0002-3498-2482